Thomas Weiner
Hematology & Oncology · Helena, MTNPI 1538260179
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,963 of the $13,867 with a category attached, or 71.8%. 37 manufacturers reported payments, led by AstraZeneca at 29.9% of the total. Reporting peaked in 2021 at $7,935 and has fallen 55.1% since, to $3,564 in 2022. Among hematology & oncology clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $76.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- EMD Serono, Inc.$3K
- Gilead$2K
- Karyopharm Therapeutics Inc.$1K
- Daiichi Sankyo Inc.$1K
- Beigene, Ltd.$525
- plus $2K from 31 others
What the payments were for
- Consulting fees$9,96372%
- Speaking & faculty fees$1,3009%
- Travel & lodging$1701%
- Food & beverage$2,23316%
- Education$2011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $4,145 |
| EMD Serono, Inc. | 2 | $2,570 |
| Gilead(2 entities) | 2 | $1,712 |
| Karyopharm Therapeutics Inc. | 1 | $1,300 |
| Daiichi Sankyo Inc. | 3 | $1,120 |
| Beigene, Ltd. | 1 | $525 |
| E.r. Squibb & Sons, L.L.C. | 26 | $355 |
| Genentech USA, Inc. | 20 | $214 |
| Novocure GmbH | 1 | $200 |
| Pfizer | 21 | $193 |
| Novartis | 12 | $182 |
| Eisai Inc. | 10 | $170 |
| Merck | 12 | $167 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $165 |
| Amgen | 12 | $143 |
| Seagen Inc. | 5 | $115 |
| Bristol Myers Squibb | 6 | $94 |
| Johnson & Johnson(2 entities) | 4 | $66 |
| EUSA Pharma (US) LLC | 2 | $42 |
| Lilly USA, LLC | 3 | $42 |
| Puma Biotechnology, Inc. | 3 | $41 |
| Bayer | 2 | $36 |
| Agios Pharmaceuticals, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Sanofi | 2 | $29 |
| Clovis Oncology, Inc. | 2 | $22 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Incyte Corporation | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Exelixis Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Array Biopharma Inc | 1 | $11 |
| Foundation Medicine, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,867 in reported general payments places this provider in the 95th percentile of 37 hematology & oncology providers in Montana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carvedilol | 17 | $178 |
| Citalopram HbrCitalopram Hydrobromide | 14 | $128 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Helena
- Patrick CobbBillings$21K
- Aaron FrankeSidney$11K
- Carolyn AksHavre$9K
- Karl GuterGreat Falls$9K
- Thomas WarrGreat Falls$8K
- Patrick TangGreat Falls$7K
- Jessica KaaeGreat Falls$6K
- Mark HancockBozeman$6K
- James HueftleAnaconda$5K
- Jennifer CarterGreat Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.